Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HF

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Aptamer Proteomics for Biomarker Discovery in Heart Failure with Reduced Ejection Fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Diagnostic and prognostic value of the electrocardiogram in stable outpatients with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Long-term effects of cardiac rehabilitation after heart valve surgery - results from the randomised CopenHeartVR trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Carly Adamson
  • Kieran F Docherty
  • Hiddo J L Heerspink
  • Rudolf A de Boer
  • Kevin Damman
  • Silvio E Inzucchi
  • Lars Køber
  • Mikhail N Kosiborod
  • Felipe A Martinez
  • Mark C Petrie
  • Piotr Ponikowski
  • Marc S Sabatine
  • Morten Schou
  • Scott D Solomon
  • Subodh Verma
  • Olof Bengtsson
  • Anna Maria Langkilde
  • Mikaela Sjöstrand
  • Muthiah Vaduganathan
  • Pardeep S Jhund
  • John J V McMurray
Vis graf over relationer

BACKGROUND: In a post hoc analysis, the frequency of occurrence of an early decline (dip) in estimated glomerular filtration rate (eGFR) after initiation of dapagliflozin and its association with outcomes were evaluated in patients with heart failure and reduced ejection fraction randomized in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial.

METHODS: Patients with heart failure with reduced ejection fraction with or without type 2 diabetes and an eGFR ≥30 mL·min-1·1.73 m-2 were randomized to placebo or dapagliflozin 10 mg daily. The primary outcome was the composite of worsening heart failure or cardiovascular death. The extent of the dip in eGFR between baseline and 2 weeks, patient characteristics associated with a >10% decline, and cardiovascular outcomes and eGFR slopes in participants experiencing this decline were investigated. Time-to-event outcomes were assessed in Cox regression from 14 days; eGFR slopes were assessed with repeated-measures mixed-effect models.

RESULTS: The mean change in eGFR between day 0 and 14 was -1.1 mL·min-1·1.73 m-2 (95% CI, -1.5 to -0.7) with placebo and -4.2 mL·min-1·1.73 m-2 (95% CI, -4.6 to -3.9) with dapagliflozin, giving a between-treatment difference of 3.1 mL·min-1·1.73 m-2 (95% CI, 2.6-3.7). The proportions of patients randomized to dapagliflozin experiencing a >10%, >20%, and >30% decline in eGFR were 38.2%, 12.6%, and 3.4%, respectively; for placebo, they were 21.0%, 6.4%, and 1.3%, respectively. The odds ratio for a >10% early decline in eGFR with dapagliflozin compared with placebo was 2.36 (95% CI, 2.07-2.69; P<0.001). Baseline characteristics associated with a >10% decline in eGFR on dapagliflozin were older age, lower eGFR, higher ejection fraction, and type 2 diabetes. The hazard ratio for the primary outcome in patients in the placebo group experiencing a >10% decline in eGFR compared with ≤10% decline in eGFR was 1.45 (95% CI, 1.19-1.78). The corresponding hazard ratio in the dapagliflozin group was 0.73 (95% CI, 0.59-0.91; Pinteraction<0.001). A >10% initial decline in eGFR was not associated with greater long-term decline in eGFR or more adverse events.

CONCLUSIONS: The average dip in eGFR after dapagliflozin was started was small and associated with better clinical outcomes compared with a similar decline on placebo in patients with heart failure with reduced ejection fraction. Large declines in eGFR were uncommon with dapagliflozin.

REGISTRATION: URL: https://www.

CLINICALTRIALS: gov; Unique identifier: NCT03036124.

OriginalsprogEngelsk
TidsskriftCirculation
Vol/bind146
Udgave nummer6
Sider (fra-til)438-449
Antal sider12
ISSN0009-7322
DOI
StatusUdgivet - 9 aug. 2022

ID: 78362972